Common questions about Gleolan (FAQ)
Q: Is Gleolan used for all types of brain tumors or just certain ones?
Official product information states that Gleolan is specifically indicated for use in adult patients who have suspected or confirmed malignant glioma, which are classified as WHO Grade III or IV tumors. It is used as an intraoperative aid during surgical resection of these tumors.
Q: How long does the effect of Gleolan last during the surgery?
The drug is administered a specific time—about 3 hours—before the patient receives anesthesia for the surgery. Regulatory documents specify that the drug’s effectiveness window is limited; if the surgical procedure is delayed by more than 12 hours after administration, the procedure requires rescheduling and a new dose according to regulatory protocol.
Q: What are the most common side effects patients experience with Gleolan?
Studies indicate that the most common side effects, occurring in 10% or more of patients, include changes in blood work such as anemia (low red blood cell count) and thrombocytopenia (low platelet count). Transient increases in liver enzymes and bilirubin, which reflect temporary changes in liver function, have also been commonly reported.
Q: Is it normal to feel sensitive to light after receiving Gleolan?
Yes, due to the drug's photosensitizing nature, light sensitivity is an expected effect. Official warnings advise that there is a risk of phototoxic reactions, which resemble severe sunburn. Therefore, patients are required to rigorously limit their exposure to strong light sources, including direct sunlight and bright indoor lights, for a specific period after the drug is administered.
Q: Can Gleolan affect my vision in the long term?
The official product information notes that neurological deficits, including vision-related problems, have been reported after surgery. These events are often related to the increased extent of tissue removal achieved during the operation.
Q: What types of medications are most likely to interact negatively with Gleolan?
Official warnings strongly advise against the co-administration of two main categories of medicines. The first includes phototoxic drugs (such as certain antibiotics, diuretics, and St. John's wort) which can increase the risk of severe sunburn-like reactions. The second includes potentially hepatotoxic (liver-damaging) products, which must be avoided for 24 hours after Gleolan administration.
Q: Has Gleolan been studied for use in children with brain tumors?
The safety and effectiveness of Gleolan in patients under 18 years of age have not been established through clinical trials. Official guidance is that use in children is not recommended, and caution is advised due to the lack of sufficient data.
Q: Does Gleolan affect the recovery time after brain surgery?
Clinical data indicated an increase in serious neurological adverse events immediately following surgery in the group using the agent, which is believed to be related to the greater extent of tumor tissue removal achieved. At longer follow-up, the frequency of these events was found to be comparable between the groups.
Q: Are the potential side effects of Gleolan permanent?
The official documentation describes adverse reactions with varying durations. For instance, the increase in liver enzymes is characterized as a transient (temporary) effect. Other serious events, such as neurological deficits, are reported in the post-operative period and are related to the surgical outcome itself.
Q: How is the light used during surgery different from normal light?
Gleolan requires highly specialized equipment. The procedure must use a standard surgical operating microscope that has been adapted with a blue light source. This specialized light is required because the fluorescent molecule only 'glows' when excited by light in a specific blue-violet wavelength range.
Q: Do I need to avoid sunlight completely after getting Gleolan?
While complete avoidance is not typically required, patients are mandated to rigorously limit their exposure to strong light sources, including direct sunlight, for 48 hours to prevent severe phototoxic skin reactions.
Q: What is the recommended time frame for surgery after taking Gleolan?
The drug must be administered in a very strict time window: 3 hours prior to the patient being put under anesthesia, within an allowance of two to four hours before the start of the operation. If the surgical procedure is delayed by more than 12 hours after the patient took the drug, the procedure is required to be rescheduled for a subsequent day, and a new dose must be used.
Q: What happens to the Gleolan in the body after the surgery is over?
The active substance in Gleolan, Aminolevulinic acid (ALA), is processed by the body and eliminated relatively quickly. The mean elimination half-life for the oral solution is approximately one hour, meaning the substance is processed and removed from the body relatively quickly.
Q: What does it mean if the tumor doesn't light up brightly after Gleolan is administered?
Official warnings note that non-fluorescing tissue cannot be ruled out as tumor, as the agent is associated with the potential for false negatives. Conversely, fluorescence may also occasionally be observed in non-tumorous tissue (false positive).
Q: Is Gleolan used outside of the United States?
Yes, regulatory documentation indicates that the agent is approved and used in other major regions. For example, it is approved by the European Medicines Agency (EMA) and is available in European Union member states, often under the name Gliolan.
Q: Can patients who have had previous brain surgery still use Gleolan?
Clinical trials included patients with both newly diagnosed and recurrent malignant tumors, indicating a history of prior brain surgery does not necessarily exclude a patient from using the agent, provided they meet the other eligibility criteria.
Q: Is there a generic version of Gleolan available?
Regulatory records confirm that there is currently no approved generic version of Gleolan (aminolevulinic acid hydrochloride) available on the market in the United States.
Q: Why is Gleolan only available in certain hospitals or surgical centers?
The drug is intended only for use by trained neurosurgeons who are experienced with malignant glioma surgery and who are familiar with the required specialized surgical equipment. The need for this specific training and specialized equipment limits its availability.
Q: Does drinking alcohol affect how Gleolan works or its side effects?
While the official prescribing information does not specifically list alcohol as a direct interaction, general guidelines for medicines advise patients to discuss the use of alcohol with their healthcare team before taking any prescription drug, as it may interact with or affect the actions of various medicines.
Q: Is Gleolan painful to take or administer?
Gleolan is prepared as an oral solution that the patient swallows, rather than being given as an injection or infusion. Patient information notes that the reconstituted liquid is generally clear to yellowish in appearance and has been described as having a sour taste.
Q: Can I take vitamins or supplements before the surgery with Gleolan?
The herbal supplement St. John's wort (Hypericin extracts) is explicitly listed as a phototoxic substance that must be prohibited during the perioperative period due to the risk of severe phototoxic skin reactions. Patients are advised to review all vitamins and supplements with their medical team before the procedure, as some are explicitly prohibited.
Q: What is the average cost of Gleolan?
Gleolan is typically billed per vial, and the cost is often incorporated into the overall hospital payment for the surgical procedure. Patients are generally advised to contact their health insurance provider directly to understand their specific coverage and financial responsibilities related to the drug's use.
Q: Is it a problem if I vomit soon after taking Gleolan?
Nausea and vomiting are listed as common side effects. Since the drug has a strict and narrow timing window for administration before surgery, this situation requires immediate notification of the treating healthcare team to determine the next steps, as the timing of the dose is strictly regulated.
Q: Is Gleolan a chemotherapy drug?
No, Gleolan is not a chemotherapy drug. It is classified as an optical imaging agent and a photosensitizer prodrug. Its primary function is diagnostic—it is an intraoperative aid that helps the surgeon visualize the tumor tissue boundaries through fluorescence, rather than treating the disease itself.
Q: How is the safety of Gleolan monitored after it's used in surgery?
Safety monitoring after surgery includes observing the patient for potential adverse reactions. The patient's care team monitors for serious neurological deficits, signs of hypersensitivity reactions, and changes in liver function, especially during the first week and up to six weeks following the surgical procedure.
Q: Are there any specific rare but serious complications linked to Gleolan?
Official warnings document the potential for several serious complications. These include severe neurological deficits, such as new or worsened paralysis, hypersensitivity reactions like anaphylactic shock, and the risk of phototoxic reactions (severe sunburn).
Q: What is the half-life of Gleolan in the human body?
The active substance, Aminolevulinic acid (ALA), has a rapid elimination rate. Its mean elimination half-life is approximately one hour, meaning the substance is processed and removed from the body quickly.
Q: Do I need special sunglasses after the procedure if I used Gleolan?
Patients are required to reduce their exposure to strong light sources for 48 hours after administration. While specific details on the exact type of protection (such as special eyewear) should be discussed with the patient's care team, the requirement for light protection is based on the risk of phototoxic reactions.
Q: Can a patient with kidney or liver problems safely use Gleolan?
Official product information states that clinical trials have not been conducted in patients with significant hepatic (liver) or renal (kidney) impairment. Official guidance advises caution when using the medicine in such patients due to the limited clinical experience available for these populations.
